SI0837672T1 - Preparations and methods for the treatment of t cell mediated diseases - Google Patents

Preparations and methods for the treatment of t cell mediated diseases

Info

Publication number: SI0837672T1
Authority: SI; Slovenia
Prior art keywords: cell mediated; preparations; treatment; mediated diseases; methods
Prior art date: 1995-07-05

Application number

SI9630662T

Other languages

English (en)

Slovenian (sl)

Inventor

Irun R. Cohen

Dana Elias

Meir Shinitzky

Original Assignee

Yeda Research And Development Co. Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-05

Filing date

1996-07-02

Publication date

2004-04-30

1996-07-02 Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.

2004-04-30 Publication of SI0837672T1 publication Critical patent/SI0837672T1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Rehabilitation Therapy (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pulmonology (AREA)
Marine Sciences & Fisheries (AREA)

SI9630662T 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases SI0837672T1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IL11445895A IL114458A0 (en)	1995-07-05	1995-07-05	Therapeutic preparations for treatment of T cell mediated diseases
EP96924371A EP0837672B9 (fr)	1995-07-05	1996-07-02	Preparations et procedes de traitments de maladies mediees par les lymphocytes t
PCT/US1996/011373 WO1997002016A1 (fr)	1995-07-05	1996-07-02	Preparations et procedes de traitments de maladies mediees par les lymphocytes t

Publications (1)

Publication Number	Publication Date
SI0837672T1 true SI0837672T1 (en)	2004-04-30

Family

ID=11067727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9630662T SI0837672T1 (en)	1995-07-05	1996-07-02	Preparations and methods for the treatment of t cell mediated diseases

Country Status (22)

Country	Link
EP (1)	EP0837672B9 (fr)
JP (2)	JP4357595B2 (fr)
KR (1)	KR100435040B1 (fr)
CN (1)	CN1102382C (fr)
AT (1)	ATE254451T1 (fr)
AU (1)	AU714970B2 (fr)
CA (1)	CA2226013C (fr)
CZ (1)	CZ298A3 (fr)
DE (1)	DE69630787T2 (fr)
DK (1)	DK0837672T3 (fr)
ES (1)	ES2211963T3 (fr)
HR (1)	HRP960315A2 (fr)
HU (1)	HU223081B1 (fr)
IL (2)	IL114458A0 (fr)
MX (1)	MX9800190A (fr)
NO (1)	NO320363B1 (fr)
PT (1)	PT837672E (fr)
SI (1)	SI0837672T1 (fr)
UY (1)	UY24275A1 (fr)
WO (1)	WO1997002016A1 (fr)
YU (1)	YU40796A (fr)
ZA (1)	ZA965666B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5993803A (en) *	1996-08-30	1999-11-30	Yeda Research And Development Co., Ltd.	Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) *	1996-11-29	2000-02-08	The Regents Of The University Of California	Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
IL142536A0 (en) *	2001-04-11	2002-03-10	Yeda Res & Dev	Carriers for therapeutic preparations for treatment of t-cell mediated diseases
ES2433915T3 (es)	2002-05-21	2013-12-13	Irun R. Cohen	Vacunas de ADN que codifican proteínas de choque térmico
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (fr) *	2003-05-12	2004-11-18	Peptor Ltd.	Compositions et procedes de modulation d'epitopes de hsp60 specifiques
WO2005048914A2 (fr) *	2003-11-24	2005-06-02	Yeda Research & Development Co. Ltd.	Vaccins d'adn codant pour des fragments de peptide hsp60 permettant de traiter les maladies auto-immunes
US8691772B2 (en)	2005-01-04	2014-04-08	Yeda Research And Development Co. Ltd.	HSP60, HSP60 peptides and T cell vaccines for immunomodulation
JP2009508517A (ja)	2005-09-22	2009-03-05	コーエン，イルン，アール	Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド
EP3448415A4 (fr) *	2016-04-29	2019-11-06	Araim Pharmaceuticals, Inc.	Peptides protecteurs tissulaires permettant de prévenir et traiter des maladies et des troubles associés à une lésion tissulaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4395394A (en) *	1979-10-26	1983-07-26	Pfizer Inc.	Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) *	1981-09-04	1985-07-31	Yeda Res & Dev	Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) *	1990-03-30	2005-05-17	Brigham & Womens Hospital	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

1995
- 1995-07-05 IL IL11445895A patent/IL114458A0/xx unknown
1996
- 1996-07-02 KR KR10-1998-0700036A patent/KR100435040B1/ko not_active Expired - Fee Related
- 1996-07-02 CN CN96196402A patent/CN1102382C/zh not_active Expired - Lifetime
- 1996-07-02 CA CA2226013A patent/CA2226013C/fr not_active Expired - Lifetime
- 1996-07-02 MX MX9800190A patent/MX9800190A/es unknown
- 1996-07-02 IL IL12275596A patent/IL122755A/en not_active IP Right Cessation
- 1996-07-02 DK DK96924371T patent/DK0837672T3/da active
- 1996-07-02 AT AT96924371T patent/ATE254451T1/de active
- 1996-07-02 JP JP50531797A patent/JP4357595B2/ja not_active Expired - Lifetime
- 1996-07-02 DE DE69630787T patent/DE69630787T2/de not_active Expired - Lifetime
- 1996-07-02 AU AU64844/96A patent/AU714970B2/en not_active Expired
- 1996-07-02 HU HU9802834A patent/HU223081B1/hu active IP Right Grant
- 1996-07-02 WO PCT/US1996/011373 patent/WO1997002016A1/fr not_active Ceased
- 1996-07-02 EP EP96924371A patent/EP0837672B9/fr not_active Expired - Lifetime
- 1996-07-02 CZ CZ982A patent/CZ298A3/cs unknown
- 1996-07-02 PT PT96924371T patent/PT837672E/pt unknown
- 1996-07-02 ES ES96924371T patent/ES2211963T3/es not_active Expired - Lifetime
- 1996-07-02 SI SI9630662T patent/SI0837672T1/xx unknown
- 1996-07-04 ZA ZA965666A patent/ZA965666B/xx unknown
- 1996-07-04 HR HR114458A patent/HRP960315A2/hr not_active Application Discontinuation
- 1996-07-05 UY UY24275A patent/UY24275A1/es unknown
- 1996-07-05 YU YU40796A patent/YU40796A/sh unknown
1998
- 1998-01-02 NO NO19980013A patent/NO320363B1/no not_active IP Right Cessation
2009
- 2009-06-15 JP JP2009141914A patent/JP2009242412A/ja active Pending

Also Published As

Publication number	Publication date
HUP9802834A3 (en)	2001-08-28
ATE254451T1 (de)	2003-12-15
ZA965666B (en)	1997-01-27
NO320363B1 (no)	2005-11-28
AU714970B2 (en)	2000-01-13
ES2211963T3 (es)	2004-07-16
DE69630787T2 (de)	2004-10-07
YU40796A (sh)	1998-11-05
CA2226013A1 (fr)	1997-01-23
EP0837672A4 (fr)	1999-01-27
CA2226013C (fr)	2012-09-18
AU6484496A (en)	1997-02-05
CZ298A3 (cs)	1998-06-17
UY24275A1 (es)	2000-12-29
HRP960315A2 (en)	1998-02-28
PT837672E (pt)	2004-03-31
EP0837672B1 (fr)	2003-11-19
KR100435040B1 (ko)	2004-08-18
NO980013D0 (no)	1998-01-02
DE69630787D1 (de)	2003-12-24
CN1102382C (zh)	2003-03-05
HUP9802834A2 (hu)	1999-03-29
MX9800190A (es)	1998-04-30
IL122755A (en)	2004-07-25
KR19990028738A (ko)	1999-04-15
IL122755A0 (en)	1998-08-16
CN1193907A (zh)	1998-09-23
DK0837672T3 (da)	2004-03-22
EP0837672B9 (fr)	2005-06-15
JP4357595B2 (ja)	2009-11-04
EP0837672A1 (fr)	1998-04-29
JPH11508899A (ja)	1999-08-03
WO1997002016A1 (fr)	1997-01-23
IL114458A0 (en)	1995-11-27
HU223081B1 (hu)	2004-03-29
NO980013L (no)	1998-02-19
JP2009242412A (ja)	2009-10-22

Publication	Publication Date	Title
ZA965666B (en)	1997-01-27	Preparations and methods for the treatment of t cell mediated diseases
ES2179077T3 (es)	2003-01-16	Acido glutamico decarboxilasa clonada.
ES2530769T3 (es)	2015-03-05	Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
PT1131065E (pt)	2003-10-31	Fumaratos dialquilicos para o tratamento de doencas autoimunes
EP0751781A4 (fr)	1999-09-22	Procede de prevention ou de traitement de maladies caracterisees par des cellules neoplasiques exprimant le cd40
AU3844297A (en)	1998-03-06	Treatment of autoimmune diseases
SI1270595T1 (sl)	2008-12-31	Protitelo proti CCR4 in njegov fragment
ATE206041T1 (de)	2001-10-15	Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ES2153665T3 (es)	2001-03-01	Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
ES2164914T3 (es)	2002-03-01	Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69719754D1 (de)	2003-04-17	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT879056E (pt)	2002-10-31	Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
PT952772E (pt)	2005-07-29	Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
IT1319275B1 (it)	2003-09-26	Uso del baclofen nel trattamento dell'astinenza da etanolo.
Chen	2018	What's new about the mechanism of methotrexate action in psoriasis?
PT782630E (pt)	2006-06-30	Gene da doenca poliquistica do rim
HUP9901077A2 (hu)	1999-07-28	Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
Ishida et al.	1994	Nutritional and immunological assessment in patients with malignant obstructive jaundice--the influence of preoperative biliary decompression and abdominal surgery
Wrigley et al.	1967	Normal cerebral function with bilateral carotid occlusion
UA28518A (uk)	2000-10-16	Спосіб визначення алергену у хворих на лікарську хворобу
Novales-Li	1996	In vitro immunopharmacologic effect of suramin on modifying Th-subset cytokine levels in splenocytes and T-cell clones: a therapeutic application for autoimmune disease
Plana	1997	Tematica delirante psicotica en psicopatologia de la expresion pictoria. Mitologemas.
WO2001038394A3 (fr)	2002-05-02	Polypeptides et methodes de vaccination thymique
UA6640A (uk)	1994-12-29	Спосіб прогнозування загострення супутнього захворювання при активізації основної патології
UA34283A (uk)	2001-02-15	Спосіб діагностики порушень імунологічного статусу у людини та тварин